This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 ETFs for Value-Based Pharma Believers

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( ETF Expert) -- Abbott Laboratories (ABT) sports five-year dividend growth of nearly 10% as well as a 3.5%+ annualized yield. Eli Lilly (LLY) has a P/E of 9, a 5.3% dividend yield and three-year earnings growth of 19%. Meanwhile, AstraZeneca (AZN) has a mammoth 35% trailing return on equity with a 5.8% annual dividend payout.

How in the world are investors overlooking the pharma space? Actually, the smart money hasn't overlooked it. The iShares DJ Pharmaceuticals Fund (IHE) is part of a select group of stock ETFs with a price above a 200-day moving average. In fact, not many stock ETFs in that select group can lay claim to year-to-date gains of about 8%.

There are four pharmaceutical ETFs for those intrigued by a value-driven uptrend. Each tends to capitalize on slightly different aspects of the drug universe. For example, SPDR S&P Pharma (XPH) maintains an equal weight strategy across 30 companies, which may lead to a greater focus on growth from the "anti Johnson & Johnsons." It follows that the yield is less compelling, but the potential for capital appreciation may be much greater.

The aforementioned IHE is relatively similar to XPH; both are less yield-oriented than pharma stocks are known for. That said, IHE is 1/4 less volatile than the S&P 500 whereas XPH is only a "skosh" less volatile than the U.S. benchmark.

In complete contrast, the Pharmaceutical HOLDRS (PPH) is dominated by Johnson & Jonhson (JNJ) with a 25% allocation. With only a handful of the largest brand name constituents moving PPH's needle -- Merck, Eli Lilly, Pfizer, etc. -- the yield is more compelling (approx 3%), but the growth prospects are less so.

The PowerShares Dynamic Pharmaceuticals Fund (PJP) rounds out the field. Its tracking of a proprietary Intellidex Index has led to superior bull market performance. Here are the 4 choices since the March 9, 2009 lows:

Perhaps ironically, three of the Pharma ETF choices don't provide enough dividend yield, making the investor rely almost entirely on capital appreciation in bull market uptrends. The other, PPH, is so wrapped up in JNJ, one can't escape the company's decade-long underachievement.

It follows that there may be a sweeter way to get your cake (yield) and eat it too (capital appreciation). Consider a fifth option -- the i Shares High Dividend Equity Fund (HDV). You get 27% exposure to "Big Pharma" as well as a 30-day, annualized SEC yield of 4%. And, HDV has done a fine job picking up "cap app" to boot.
Disclosure Statement: ETF Expert is a website that makes the world of ETFs easier to understand. Gary Gordon, Pacific Park Financial and/or its clients may hold positions in ETFs, mutual funds and investment assets mentioned. The commentary does not constitute individualized investment advice. The opinions offered are not personalized recommendations to buy, sell or hold securities. At times, issuers of exchange-traded products compensate Pacific Park Financial or its subsidiaries for advertising at the ETF Expert website. ETF Expert content is created independently of any advertising relationships. You may review additional ETF Expert at the site.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
PJP $73.25 0.47%
HDV $74.40 0.40%
IHE $161.50 0.23%
XPH $53.86 0.77%
PPH $64.63 -0.22%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs